| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Departments of Dermatology [S. R. F., A. A., D. G.], Oncological Sciences [D. G.], and the Huntsman Cancer Institute [S. M. A., A. N. H., M. J. D., D. G.], University of Utah, Salt Lake City, Utah 84112, and Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605 [D. C. A.]
Induction of cutaneous squamous cell carcinoma (SCC) in mice, by topical chemical [9,10-dimethylbenzanthracene (DMBA) and phorbol 12-myristate 13-acetate (PMA)] application, is a multistep process involving papilloma formation and progression to carcinoma. We have generated a transgenic (Tg) mouse [keratin-14 (K14)-survivin] with skin expression of survivin, an inhibitor of apoptosis expressed in most human skin cancers and premalignant lesions. K14-survivin mice were resistant to DMBA-induced keratinocyte apoptosis. To investigate the role of survivin and apoptosis in cutaneous carcinogenesis, mice were treated once topically with DMBA followed by twice weekly with PMA for 32 weeks. Surprisingly, tumor formation was less frequent (31% versus 43%) and significantly delayed (P = 0.01) in K14-survivin mice compared with non-Tg littermates. On the other hand, papilloma regression was not observed in Tg mice, whereas 20% of papillomas regressed in non-Tgs; one SCC was generated in Tg mice, whereas none were seen in non-Tgs. To increase tumor formation and SCC in particular, a second experiment was performed with mice on a p53+/- background. Again, DMBA/PMA-induced tumor formation was less (71% versus 89%) and significantly delayed (P = 0.02) in K14-survivin p53+/- animals compared with p53+/- non-Tgs. Papilloma regression was also not observed in Tg p53+/- mice, whereas 10% of papillomas regressed in p53+/- non-Tgs. The rate of papilloma progression to SCC was 21% in Tg p53+/- mice compared with 12% in p53+/- non-Tgs. Papillomas did not reveal significant differences in mitotic or apoptotic indices. Survivin expression was detected in all of the tumors. These results indicate that despite a paradoxical negative effect on tumor formation, survivin expression prevents papilloma regression and promotes conversion to SCC, consistent with its expression in most skin cancers and their precursors.
This article has been cited by other articles:
![]() |
I. Abd-Elrahman, K. Hershko, T. Neuman, B. Nachmias, R. Perlman, and D. Ben-Yehuda The Inhibitor of Apoptosis Protein Livin (ML-IAP) Plays a Dual Role in Tumorigenicity Cancer Res., July 1, 2009; 69(13): 5475 - 5480. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ando, R. Abe, M. Sasaki, J. Murata, D. Inokuma, and H. Shimizu Bone Marrow-Derived Cells Are Not the Origin of the Cancer Stem Cells in Ultraviolet-Induced Skin Cancer Am. J. Pathol., February 1, 2009; 174(2): 595 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thomas, T. Liu, M. A. Cotter, S. R. Florell, K. Robinette, A. N. Hanks, and D. Grossman Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic Mice Cancer Res., June 1, 2007; 67(11): 5172 - 5178. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gerl and D. L. Vaux Apoptosis in the development and treatment of cancer Carcinogenesis, February 1, 2005; 26(2): 263 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang, A. N. Hanks, K. Boucher, S. R. Florell, S. M. Allen, A. Alexander, D. E. Brash, and D. Grossman UVB-induced apoptosis drives clonal expansion during skin tumor development Carcinogenesis, January 1, 2005; 26(1): 249 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mallikarjuna, S. Dhanalakshmi, R. P. Singh, C. Agarwal, and R. Agarwal Silibinin Protects against Photocarcinogenesis via Modulation of Cell Cycle Regulators, Mitogen-Activated Protein Kinases, and Akt Signaling Cancer Res., September 1, 2004; 64(17): 6349 - 6356. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. P. Blanc-Brude, M. Mesri, N. R. Wall, J. Plescia, T. Dohi, and D. C. Altieri Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-associated Angiogenesis Clin. Cancer Res., July 1, 2003; 9(7): 2683 - 2692. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |